Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease

Basit Öğe Kaydı
dc.contributor.authorMenekşe, Burak
dc.contributor.authorBatman, Adnan
dc.date.accessioned2023-10-24T10:33:25Z
dc.date.available2023-10-24T10:33:25Z
dc.date.issued2023
dc.departmentTıp Fakültesi
dc.description.abstractDiabetes mellitus is a chronic disease often associated with nonalcoholic steatohepatitis (NASH) and obesity. Both obesity and NASH are closely related to inflammation. In this study, we examined how exenatide, a glucagon-like peptide 1 analog, affects inflammatory and NASH-related markers in patients with diabetes. Methods: This retrospective study was conducted on 100 patients who visited our hospital with a diagnosis of type 2 diabetes mellitus. NASH-related indices and inflammatory indices were calculated from data obtained at baseline and at the third month of exenatide treatment. All data were analyzed first in all patients, and then the patients were grouped according to glycosylated hemoglobin A1c (HbA1c) levels of <8% or ?8% and body mass index (BMI) of <40 or ?40 kg/m2 and their data were reanalyzed. Results: A highly significant improvement was found in the conventional lipid profile. Among NASH-related indices, the nonalcoholic fatty liver disease (NAFLD) fibrosis score and aspartate aminotransferase-platelet ratio index (APRI) showed statistically significant decreases (P < 0.001 and P = 0.016, respectively). In particular, these significant decreases were independent of BMI and glycemic parameters. No statistically significant change was found in inflammatory indices. The decreases in NAFLD fibrosis score and APRI were statistically more significant in the group with HbA1c ?8% (P = 0.021 and P = 0.002, respectively) and the group with BMI ?40 kg/m2 (P = 0.002 and P = 0.029, respectively). Conclusions: Besides its established effects, such as lowering fasting plasma glucose levels and weight loss, exenatide exerts positive effects on the conventional lipid profile and NASH-associated indexes.
dc.identifier.doi10.1089/met.2022.0088
dc.identifier.endpage213en_US
dc.identifier.issue4en_US
dc.identifier.startpage205en_US
dc.identifier.urihttps:/dx.doi.org10.1089/met.2022.0088
dc.identifier.urihttps://hdl.handle.net/20.500.12451/11214
dc.identifier.volume21en_US
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLarchmont
dc.relation.ispartofMetabolic Syndrome and Related Disorder
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGLP-1 Analogue
dc.subjectNASH
dc.subjectExenatide
dc.subjectInflammation
dc.subjectType 2 Diabetes Mellitus
dc.titleEffect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu